Lb Pharmaceuticals INC 8-K filings

LB Pharmaceuticals announced accelerated topline data for its LB-102 schizophrenia trial, plans pipeline expansion, and secured $150 million in funding.

LB Pharmaceuticals Inc. announced a $150 million private placement of common stock and pre-funded warrants to institutional investors to fund pipeline expansion and general corporate purposes.

LB Pharmaceuticals announced accelerated timing for topline results from its Phase 3 NOVA-2 clinical trial for schizophrenia drug LB-102, now expected in the first half of 2027.

LB Pharmaceuticals Chief Medical Officer Dr. Anna Eramo will resign effective June 15, 2026, transitioning to a consulting role through September 15, 2026.

LB Pharmaceuticals Inc. reports final voting results from its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

LB Pharmaceuticals announced Q1 2026 financial results, highlighting progress in late-stage clinical trials for LB-102 and securing $100 million in private placement funding.

LB Pharmaceuticals announced positive Phase 2 results for LB-102 in schizophrenia, initiated pivotal late-stage trials, and secured significant funding, extending its cash runway into Q2 2029.

LB Pharmaceuticals Inc. announced that director Zachary Prensky will retire from the Board and transition to a consulting role.

LB Pharmaceuticals Inc. announced a $100 million private placement to fund a Phase 2 clinical trial for LB-102, targeting major depressive disorder.

LB Pharmaceuticals Inc. has signed an amendment to its lease, securing an additional 4,634 square feet of office space in New York City.

LB Pharmaceuticals Inc. announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, to lead commercialization efforts for its lead drug candidate, LB-102.

LB Pharmaceuticals Inc. announced its third-quarter 2025 financial results and provided updates on the advancement of its lead product candidate, LB-102, into Phase 3 and Phase 2 trials.

LB Pharmaceuticals Inc. filed an amended and restated certificate of incorporation and bylaws, effective September 12, 2025, in connection with the closing of its initial public offering.